BCTXL · BriaCell Therapeutics Corp. · Executive Compensation
$0.93
+0.03 (+3.33%)
At close · Oct 21
Return incl. dividend (before tax)
Going-concern doubt
— flagged Jun 9, 2026
Substantial doubt about the company's ability to continue as a going concern.
“However, the Company's ability to continue as a going concern is dependent upon its ability to attain future profitable operations and to continue to obtain the necessary financing to meet its obligations arising from normal business operations when they come due. The uncertainty of the Company's ability to raise such financial capital casts substantial doubt on the Company's ability to continue as a going concern.”View the 10-Q filed Jun 9, 2026
Market Cap
$31.54M
Shares
8.70M
Volume · Oct 21
17.14K
Avg daily vol (43 sessions)
16.28K
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
No Compensation Data
No Summary Compensation Table has been imported from this company's proxy statements yet.
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Marc Lustig | board of directors | Resigned | 2024-11-25 |
Leadership
- Dr. William V. Williams CEO, Board Member
- Mr. Gadi Levin CFO
- Dr. Jane Gross Board Member
- Dr. Rebecca Taub Board Member
- Dr. Vaughn C. Embro-Pantalony Board Member
- Mr. Jamieson Bondarenko Board Member
- Mr. Martin Schmieg Board Member